Laura A. Healy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura A. Healy has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- John Vincent Reynolds
Trinity St. James’s Cancer Institute, Dublin, Ireland
5 shared publications - Aoife M. Ryan
School of Food and Nutritional Sciences, College of Science, Engineering and Food Science, University College Cork, Cork, Ireland; Cancer Research @UCC University College Cork, Cork, Ireland
4 shared publications - Brian J. Mehigan
Department of Colorectal Surgery, St James’s Hospital, Dublin 8, Ireland
2 shared publications - Narayanasamy Ravi
Department of Upper GI Surgery, National Centre for Esophageal and Gastric Cancer, Trinity St. James’s Cancer Institute, St James’s Hospital, D08 NHY1 Dublin, Ireland
2 shared publications S. Doyle
2 shared publicationsA. McHugh
1 shared publication
Latest Publications
- 1 September 2016
- Published by Elsevier in Clinical Nutrition
- Vol. 35, S17-S18
OR43: Double Blinded, Placebo Controlled Eicosapentaenoic Acid (EPA) Enriched Enteral Nutrition in the Surgical Treatment of Oesophageal Cancer Patients
- 1 September 2016
- Published by Elsevier in Clinical Nutrition
- Vol. 35, S17-S18
OR43: Double Blinded, Placebo Controlled Eicosapentaenoic Acid (EPA) Enriched Enteral Nutrition in the Surgical Treatment of Oesophageal Cancer Patients
- 1 September 2016
- Published by Elsevier in Clinical Nutrition
- Vol. 35, S38
PT08.4: Beneifts of Increased Perioperative Nutrition Support Postoesophagectomy
- 1 September 2016
- Published by Elsevier in Clinical Nutrition
- Vol. 35, S38
PT08.4: Beneifts of Increased Perioperative Nutrition Support Postoesophagectomy
- 10 January 2011
- Published by Wiley in Colorectal Disease
- Vol. 14 (2) , 157-165
Metabolic syndrome and leptin are associated with adverse pathological features in male colorectal cancer patients
Aim Metabolic syndrome (MetS) describes a clustering of factors including central obesity, hypertension and raised plasma glucose, triglycerides and high‐density lipoprotein (HDL) cholesterol. Central obesity is associated with a risk for colorectal cancer, but the impact of MetS on colorectal cancer biology and outcomes is unclear. Method A prospective observational study of colorectal cancer patients was carried out in an Irish population. Patients underwent metabolic and anthropometric assessment before treatment, including measurement of serum hormones and adipokines and CT measurement of visceral fat. MetS was defined according to the International Diabetes Federation definition3. Results One‐hundred and thirty consecutive colorectal cancer patients (66 men and 64 women) were recruited. MetS was diagnosed in 38% patients compared with the population norms reported at 21%21. Male patients had a significantly greater visceral fat area compared with female patients. MetS was associated with node‐positive disease (P = 0.026), percentage nodal involvement (P = 0.033) and extramural vascular invasion (P = 0.049) in male patients but no significant association was observed in female patients. HDL cholesterol was also significantly associated with a more advanced pathological stage (P = 0.014) and node‐positive disease (P = 0.028). Leptin was associated with nodal status (P = 0.036), microvascular invasion (P = 0.054), advanced pathological stage (P = 0.046) and more advanced Dukes stage (P = 0.042). Conclusion We report a high prevalence of MetS and visceral obesity in a colorectal cancer population. MetS and plasma leptin are associated with a more aggressive tumour phenotype in male patients only.
- 10 January 2011
- Published by Wiley in Colorectal Disease
- Vol. 14 (2) , 157-165
Metabolic syndrome and leptin are associated with adverse pathological features in male colorectal cancer patients
Aim Metabolic syndrome (MetS) describes a clustering of factors including central obesity, hypertension and raised plasma glucose, triglycerides and high‐density lipoprotein (HDL) cholesterol. Central obesity is associated with a risk for colorectal cancer, but the impact of MetS on colorectal cancer biology and outcomes is unclear. Method A prospective observational study of colorectal cancer patients was carried out in an Irish population. Patients underwent metabolic and anthropometric assessment before treatment, including measurement of serum hormones and adipokines and CT measurement of visceral fat. MetS was defined according to the International Diabetes Federation definition3. Results One‐hundred and thirty consecutive colorectal cancer patients (66 men and 64 women) were recruited. MetS was diagnosed in 38% patients compared with the population norms reported at 21%21. Male patients had a significantly greater visceral fat area compared with female patients. MetS was associated with node‐positive disease (P = 0.026), percentage nodal involvement (P = 0.033) and extramural vascular invasion (P = 0.049) in male patients but no significant association was observed in female patients. HDL cholesterol was also significantly associated with a more advanced pathological stage (P = 0.014) and node‐positive disease (P = 0.028). Leptin was associated with nodal status (P = 0.036), microvascular invasion (P = 0.054), advanced pathological stage (P = 0.046) and more advanced Dukes stage (P = 0.042). Conclusion We report a high prevalence of MetS and visceral obesity in a colorectal cancer population. MetS and plasma leptin are associated with a more aggressive tumour phenotype in male patients only.
- 20 June 2010
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 25 (11) , 1293-1299
Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer
Introduction Obesity is an established risk factor for colorectal cancer, particularly in males, and may negatively impact on oncologic outcomes. The aim of this study was to examine the impact of body mass index (BMI) on mortality and morbidity, tumour pathology, and overall survival in a consecutive cohort of Irish colorectal cancer patients treated with curative intent. Methods A retrospective analysis of BMI data entered prospectively into a comprehensive electronic database of colorectal cancer patients was undertaken. Patients were excluded if they had emergency surgery, previous malignancy or the BMI was not recorded. Analysis was performed comparing genders, obese with non-obese and comparing BMI categories. Results Of the 414 patients, 10% were underweight (2); 35% were normal weight (20–25 kg/m2); 37% were overweight (25–30 kg/m2), and 18% were obese (≥30.00 kg/m2). Obesity overall was not significantly associated with pathological stage (p = 0.099) or positive lymph node status (p = 0.109) or degree of nodal involvement (p = 0.068). Obesity was significantly (pp = 0.244) and minor complications (p = 0.078) when comparing obese with non-obese, but pelvic abscesses were more common in obese patients (p = 0.037). The underweight cohort had a higher rate of major complications (p = 0.041), sepsis (p = 0.024) and post-operative death (p = 0.006). Survival was equivalent between BMI categories and obese and non-obese groups (p = 0.469). Conclusion Obesity was associated with more advanced tumours in males and in colon cancer patients only and with a higher risk of post-operative pelvic abscesses but no significant differences with non-obese cohorts in the main outcome measures of in-hospital mortality, major morbidity and survival. Conversely, the adverse consequences of under-nutrition were highlighted in this study.
- 20 June 2010
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 25 (11) , 1293-1299
Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer
Introduction Obesity is an established risk factor for colorectal cancer, particularly in males, and may negatively impact on oncologic outcomes. The aim of this study was to examine the impact of body mass index (BMI) on mortality and morbidity, tumour pathology, and overall survival in a consecutive cohort of Irish colorectal cancer patients treated with curative intent. Methods A retrospective analysis of BMI data entered prospectively into a comprehensive electronic database of colorectal cancer patients was undertaken. Patients were excluded if they had emergency surgery, previous malignancy or the BMI was not recorded. Analysis was performed comparing genders, obese with non-obese and comparing BMI categories. Results Of the 414 patients, 10% were underweight (2); 35% were normal weight (20–25 kg/m2); 37% were overweight (25–30 kg/m2), and 18% were obese (≥30.00 kg/m2). Obesity overall was not significantly associated with pathological stage (p = 0.099) or positive lymph node status (p = 0.109) or degree of nodal involvement (p = 0.068). Obesity was significantly (pp = 0.244) and minor complications (p = 0.078) when comparing obese with non-obese, but pelvic abscesses were more common in obese patients (p = 0.037). The underweight cohort had a higher rate of major complications (p = 0.041), sepsis (p = 0.024) and post-operative death (p = 0.006). Survival was equivalent between BMI categories and obese and non-obese groups (p = 0.469). Conclusion Obesity was associated with more advanced tumours in males and in colon cancer patients only and with a higher risk of post-operative pelvic abscesses but no significant differences with non-obese cohorts in the main outcome measures of in-hospital mortality, major morbidity and survival. Conversely, the adverse consequences of under-nutrition were highlighted in this study.
- 1 May 2010
- Published by Elsevier in Clinical Oncology
- Vol. 22 (4) , 281-288
Metabolic Syndrome, Central Obesity and Insulin Resistance are Associated with Adverse Pathological Features in Postmenopausal Breast Cancer
- 1 May 2010
- Published by Elsevier in Clinical Oncology
- Vol. 22 (4) , 281-288
Metabolic Syndrome, Central Obesity and Insulin Resistance are Associated with Adverse Pathological Features in Postmenopausal Breast Cancer
- 1 April 2010
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 23 (5) , 386-391
Lack of differential pattern in central adiposity and metabolic syndrome in Barrett's esophagus and gastroesophageal reflux disease
Obesity is an established risk factor for esophageal adenocarcinoma, although the mechanism is unclear. A pathway from reflux to inflammation through metaplasia is the dominant hypothesis, and an added role relating to visceral adiposity and the metabolic syndrome has been mooted in Barrett's esophagus (BE) patients. Whether BE differs from gastroesophageal reflux disease (GERD) in obesity and metabolic syndrome profiles is unclear, and this was the focus of this study. Patients with proven BE or GERD were randomly selected from the unit data registry and invited to attend for metabolic syndrome screening, anthropometry studies including segmental body composition analysis, and laboratory tests including fasting lipids, insulin, and C-reactive protein. Metabolic syndrome was defined using the National Cholesterol Education Program (NCEP) and the International Diabetes Federation (IDF) criteria. One hundred and eighteen BE patients and 113 age- and sex-matched GERD controls were studied. The incidence of obesity (body mass index >30 kg/m(2)) was 36% and 38%, respectively, with the pattern of fat deposition predominantly central and an estimated trunk fat mass of 13 and 14 kg, respectively. Using the NCEP criteria, metabolic syndrome was significantly more common in the BE cohort (30% vs 20%, P < 0.05), but there was no significant difference using IDF criteria (42% vs 37%, P= 0.340). Central obesity and the metabolic syndrome are common in both Barrett's and GERD cohorts, but not significantly different, suggesting that central obesity and the metabolic syndrome does not per se impact on the development of BE in a reflux population. In BE, the importance of obesity and the metabolic syndrome in disease progression merits further study.
- 1 April 2010
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 23 (5) , 386-391
Lack of differential pattern in central adiposity and metabolic syndrome in Barrett's esophagus and gastroesophageal reflux disease
Obesity is an established risk factor for esophageal adenocarcinoma, although the mechanism is unclear. A pathway from reflux to inflammation through metaplasia is the dominant hypothesis, and an added role relating to visceral adiposity and the metabolic syndrome has been mooted in Barrett's esophagus (BE) patients. Whether BE differs from gastroesophageal reflux disease (GERD) in obesity and metabolic syndrome profiles is unclear, and this was the focus of this study. Patients with proven BE or GERD were randomly selected from the unit data registry and invited to attend for metabolic syndrome screening, anthropometry studies including segmental body composition analysis, and laboratory tests including fasting lipids, insulin, and C-reactive protein. Metabolic syndrome was defined using the National Cholesterol Education Program (NCEP) and the International Diabetes Federation (IDF) criteria. One hundred and eighteen BE patients and 113 age- and sex-matched GERD controls were studied. The incidence of obesity (body mass index >30 kg/m(2)) was 36% and 38%, respectively, with the pattern of fat deposition predominantly central and an estimated trunk fat mass of 13 and 14 kg, respectively. Using the NCEP criteria, metabolic syndrome was significantly more common in the BE cohort (30% vs 20%, P < 0.05), but there was no significant difference using IDF criteria (42% vs 37%, P= 0.340). Central obesity and the metabolic syndrome are common in both Barrett's and GERD cohorts, but not significantly different, suggesting that central obesity and the metabolic syndrome does not per se impact on the development of BE in a reflux population. In BE, the importance of obesity and the metabolic syndrome in disease progression merits further study.